Online inquiry

IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11891MR)

This product GTTS-WQ11891MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CCR2 gene. The antibody can be applied in Inflammatory conditions research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001123041.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 729230
UniProt ID P41597
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11891MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10023MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA L19-131 I
GTTS-WQ835MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-155
GTTS-WQ8987MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IMA-638
GTTS-WQ5245MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CB-6
GTTS-WQ1345MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABT-806
GTTS-WQ1592MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACE-083
GTTS-WQ10501MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LY3002813
GTTS-WQ13122MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-04360365
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW